Omega Benefit ES
$ 70.00
Size: 60 Softgels
Powerful Results in One Softgel, Triple Absorption and Total Vitality
Triple Absorption. Extra Strength. Pure Omega-3 Support for Cardiovascular, Brain, and Metabolic Health.
Omega Benefit® ES delivers clinical-grade omega-3 support in an extra-strength formula designed for those who need higher therapeutic levels of EPA and DHA. Using patented MaxSimil® monoglyceride technology, this physician-formulated fish oil provides up to three times greater absorption than standard fish oils- ensuring superior cellular uptake and clinical results.*
Each enteric-coated softgel contains 1,300 mg of fish oil with a total of 860 mg of omega-3s, including 600 mg of EPA and 260 mg of DHA- essential fatty acids that promote heart, brain, and inflammatory balance. The MaxSimil® delivery system pre-emulsifies each dose, allowing for direct intestinal absorption and maximum bioavailability, even in those with digestive, pancreatic, or gallbladder challenges.*
Every batch is third-party tested and IFOS five-star certified for purity, potency, and freshness, meeting the highest global standards for sustainability and safety.
Key Benefits
- Supports cardiovascular health and healthy lipid metabolism*
- Promotes cognitive clarity, focus, and emotional balance*
- Encourages joint comfort and inflammation resolution*
- Aids healthy insulin and glucose metabolism*
- Provides 3× better absorption than conventional fish oils*
- Offers extra-strength EPA and DHA for clinical-grade support*
- Gentle on digestion—enteric coated to prevent aftertaste*
- Third-party tested and IFOS five-star certified for purity and freshness*
*These statements have not been evaluated by the FDA and are not intended to treat or cure any disease.
You’ll Enjoy Omega Benefit® ES if you…
- Need higher-level omega-3 support for cardiovascular or inflammatory health
- Want to optimize brain function, focus, and mood balance
- Have higher triglyceride levels or chronic inflammation concerns
- Prefer an easy-to-digest fish oil with no fishy aftertaste
- Value clean, sustainable, and clinically verified formulations
Our Patients Love Dr. Morrison’s Omega Benefit® ES Because…
- Fish-Gelatin Capsules
Many brands use beef gelatin capsules, which can be harder to digest and less suitable for those avoiding bovine products. Omega Benefit® uses fish-gelatin softgels, a cleaner, more compatible option for a truly marine-based supplement. - It delivers therapeutic-strength EPA and DHA with 3× superior absorption
- Each softgel is enteric-coated and easy to take daily
- It’s gentle on digestion and completely burp-free
- Every batch is IFOS five-star certified for purity, potency, and freshness
- It provides advanced cardiovascular and cognitive support trusted in clinical practice for over two decades*
1 SOFTGEL PER SERVING
Fish Oil Concentrate | 1.3 g
Total Omega-3 Fatty Acids | 860 mg
EPA (eicosapentaenoic acid) | 600 mg
DHA (docosahexaenoic acid) | 260 mg
DPA (Docosapentaenoic Acid) | 25 mg
Other Ingredients: Fish gelatin, vegetable glycerin, purified water, GRAS enteric coating (ethylcellulose, sodium alginate, medium-chain triglycerides, oleic acid, vegetable stearic acid, ammonium hydroxide), and mixed natural tocopherols.
Contains: Fish (anchovy, sardine, tilapia, pangasius)
DOES NOT CONTAIN: Wheat, gluten, corn, yeast, soy protein, dairy products, shellfish, peanuts, tree nuts, egg, GMOs, artificial colors, artificial sweeteners, or artificial preservatives.
Certification: IFOS 5-Star Certified • Third-Party Tested • Sustainably Sourced
Take 1 softgels daily, or as directed by your healthcare practitioner.
Caution: Individuals taking blood thinners or other medication should discuss potential interactions with their healthcare practitioner.
The importance of the ratio of omega-6/omega-3 essential fatty acids
Several sources of information suggest that human beings evolved on a diet with a ratio of omega-6 to omega-3 essential fatty acids (EFA) of approximately 1 whereas in Western diets the ratio is 15/1-16.7/1. Western diets are deficient in omega-3 fatty acids, and have excessive amounts of omega-6 fatty acids compared with the diet on which human beings evolved and their genetic patterns were established. Excessive amounts of omega-6 polyunsaturated fatty acids (PUFA) and a very high omega-6/omega-3 ratio, as is found in today's Western diets, promote the pathogenesis of many diseases, including cardiovascular disease, cancer, and inflammatory and autoimmune diseases, whereas increased levels of omega-3 PUFA (a low omega-6/omega-3 ratio) exert suppressive effects. In the secondary prevention of cardiovascular disease, a ratio of 4/1 was associated with a 70% decrease in total mortality. A ratio of 2.5/1 reduced rectal cell proliferation in patients with colorectal cancer, whereas a ratio of 4/1 with the same amount of omega-3 PUFA had no effect. The lower omega-6/omega-3 ratio in women with breast cancer was associated with decreased risk. A ratio of 2-3/1 suppressed inflammation in patients with rheumatoid arthritis, and a ratio of 5/1 had a beneficial effect on patients with asthma, whereas a ratio of 10/1 had adverse consequences. These studies indicate that the optimal ratio may vary with the disease under consideration. This is consistent with the fact that chronic diseases are multigenic and multifactorial. Therefore, it is quite possible that the therapeutic dose of omega-3 fatty acids will depend on the degree of severity of disease resulting from the genetic predisposition. A lower ratio of omega-6/omega-3 fatty acids is more desirable in reducing the risk of many of the chronic diseases of high prevalence in Western societies, as well as in the developing countries, that are being exported to the rest of the world.
Fish oil supplementation and insulin sensitivity: a systematic review and meta-analysis
Background: Fish oil supplementation has been shown to be associated with a lower risk of metabolic syndrome and benefit a wide range of chronic diseases, such as cardiovascular disease, type 2 diabetes and several types of cancers. However, the evidence of fish oil supplementation on glucose metabolism and insulin sensitivity is still controversial. This meta-analysis summarized the exist evidence of the relationship between fish oil supplementation and insulin sensitivity and aimed to evaluate whether fish oil supplementation could improve insulin sensitivity.
Methods: We searched the Cochrane Library, PubMed, Embase database for the relevant studies update to Dec 2016. Two researchers screened the literature independently by the selection and exclusion criteria. Studies were pooled using random effect models to estimate a pooled SMD and corresponding 95% CI. This meta-analysis was performed by Stata 13.1 software.
Results: A total of 17 studies with 672 participants were included in this meta-analysis study after screening from 498 published articles found after the initial search. In a pooled analysis, fish oil supplementation had no effects on insulin sensitivity compared with the placebo (SMD 0.17, 95%CI -0.15 to 0.48, p = 0.292). In subgroup analysis, fish oil supplementation could benefit insulin sensitivity among people who were experiencing at least one symptom of metabolic disorders (SMD 0.53, 95% CI 0.17 to 0.88, p < 0.001). Similarly, there were no significant differences between subgroups of methods of insulin sensitivity, doses of omega-3 polyunsaturated fatty acids (n-3 PUFA) of fish oil supplementation or duration of the intervention. The sensitivity analysis indicated that the results were robust.
Conclusions: Short-term fish oil supplementation is associated with increasing the insulin sensitivity among those people with metabolic disorders.